glp-1 and trump says U.S. to provide drugs for Medicare patients Awkward Moment': Dr. Oz Interrupts

Plan sponsors are currently facing critical decisions regarding GLP-1 medications which require balancing costs, member health benefits, and evolving medication landscapes

The provider reviews medication dosing and how long the patient has been taking the drug

Today, Novo Nordisk estimates that just under 20 million people are treated with GLP-1 drugs.4 Given a well-stocked pipeline, a substantial global addressable population (the obese population alone is projected to exceed 1.2 billion by 20305), and in light of the very beneficial clinical profile of these drugs, it is plausible that over 100 million patients worldwide will be treated with GLP-1s in the near future

Your provider will review all available options and help you choose the treatment plan that fits your medical needs and budget